Evidence map›Paper›PMID 41778962›Full record

ArticleThe journal of pathology. Clinical research2026

AI-derived prognostic biomarkers from melanoma whole slide image segmentation: an initial discovery and assessment.

Emily L Clarke, Derek Magee, Julia Newton-Bishop, Gerald Saldanha, William Merchant, Marlous Hall, Robert Insall, Nigel G Maher, Richard A Scolyer, Grace Farnworth and 6 more

Abstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Emily L ClarkeDepartment of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID https://orcid.org/0000-0001-7106-9898
Derek MageeSchool of Computing, University of Leeds, Leeds, UK.
Julia Newton-BishopLeeds Institute for Medical Research, University of Leeds, Leeds, UK.
Gerald SaldanhaLeicester Cancer Research Centre, University of Leicester, Leicester, UK.
William MerchantDepartment of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Marlous HallDepartment of Clinical and Population Sciences, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Robert InsallDepartment of Cell and Developmental Biology, University College London, London, UK.
Nigel G MaherMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Grace FarnworthDivision of Pathology and Data Analytics, University of Leeds, Leeds, UK.
Anisah AliDivision of Pathology and Data Analytics, University of Leeds, Leeds, UK.
Mark BamfordDepartment of Histopathology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Eva SticovaDepartment of Pathology, Third Faculty of Medicine, Charles University and Teaching Hospital Kralovske Vinohrady, Prague, Czech Republic.
Petr KujalDepartment of Pathology, Third Faculty of Medicine, Charles University and Teaching Hospital Kralovske Vinohrady, Prague, Czech Republic.
Sally O'SheaDermatology Department, South Infirmary Victoria University Hospital, Cork, Ireland.
Darren TreanorDepartment of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Funding

Alan Turing InstituteCancer Research UK C588/A10721Cancer Research UK C588/A19167Cancer Research UK C8216/A6129Cancer Research UK NIH CA83115Faculty of Medicine and Health, University of SydneyLeeds Biomedical Research Centre NIHR213331Medical Research Council MR/M019012/1Medical Research Council MR/S001530/1Melanoma Centre of Research Excellence 2022/GNT2018514Melanoma Institute AustraliaRCPA FoundationTour de CureUK Research and Innovation 104687Wellcome Trust 206470/Z/17/Z
6 · The paper itself

Abstract

The current melanoma staging system predicts 74% of the variance in survival, with prognostic biomarkers subject to high levels of inter-observer variation. This work assesses whether a previously developed convolutional neural network (CNN) for invasive melanoma segmentation in whole slide images (WSIs) may reveal new insights into melanoma morphology and patient prognosis. This paper uses Cox proportional multivariate regression analyses to evaluate the ability of the CNN outputs to predict patient survival across 745 WSIs from 5 data sources. Five objective histomorphological parameters of tumour size and shape that are independently associated with overall and melanoma-specific survival were created from the CNN: tumour area(log) (HR 1.48 CI 1.30-1.68, p < 0.001), tumour perimeter(log) (HR 1.86 CI 1.48-2.32, p < 0.001), major axis length(log) (HR 1.88 CI 1.42-2.48, p < 0.001), Nodularity Index(log) (HR 1.77 CI 1.28-2.43, p < 0.001) and digital Breslow thickness(log) (HR 2.04, CI 1.63-2.54, p < 0.001). These results indicate that melanoma segmentation of the entire lesion within a WSI may be used to predict patient outcome. Moreover, this technology can be used to make new morphological discoveries to provide information not currently contained within our staging system (e.g. Nodularity Index), as well as provide objectivity and automation of current biomarkers (e.g. digital Breslow thickness). Further work is required to validate this initial discovery and evaluation.

Indexed as

Biomarkers, TumorImage Interpretation, Computer-AssistedMelanomaSkin NeoplasmsConvolutional Neural NetworksHumansNeoplasm StagingPredictive Value of TestsPrognosisBiomarkers, Tumorartificial intelligencebiomarkersconvolutional neural networksdigital pathologyhistologymachine learningmelanoma

Identifiers

PMID41778962
PMCPMC12959248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.